Pfizer (NYSE:PFE – Get Rating) is set to announce its earnings results before the market opens on Tuesday, January 31st. Analysts expect the company to announce earnings of $1.05 per share for the quarter. Pfizer has set its FY22 guidance at $6.40-6.50 EPS and its FY 2022 guidance at $6.40-$6.50 EPS.Investors interested in listening to the company's conference call can do so using this link.
Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.31. The firm had revenue of $22.64 billion during the quarter, compared to the consensus estimate of $21.04 billion. Pfizer had a return on equity of 43.95% and a net margin of 29.81%. On average, analysts expect Pfizer to post $6 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Get Pfizer alerts:Pfizer Trading Down 1.0 %
PFE stock opened at $43.79 on Friday. The company has a market cap of $245.81 billion, a P/E ratio of 8.42, a PEG ratio of 1.09 and a beta of 0.67. Pfizer has a twelve month low of $41.44 and a twelve month high of $56.32. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 0.35. The business has a fifty day moving average of $49.45 and a 200-day moving average of $47.95.
Pfizer Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, March 3rd. Stockholders of record on Friday, January 27th will be given a dividend of $0.41 per share. The ex-dividend date of this dividend is Thursday, January 26th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.75%. This is an increase from Pfizer's previous quarterly dividend of $0.40. Pfizer's payout ratio is presently 31.54%.Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on the company. StockNews.com assumed coverage on Pfizer in a research report on Wednesday, October 12th. They set a "strong-buy" rating for the company. UBS Group downgraded Pfizer from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $55.00 to $47.00 in a research report on Thursday. The Goldman Sachs Group upgraded Pfizer from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $47.00 to $60.00 in a research report on Tuesday, December 13th. Credit Suisse Group set a $54.00 price objective on Pfizer in a research note on Wednesday, January 18th. Finally, Morgan Stanley lifted their price objective on Pfizer from $51.00 to $53.00 and gave the stock an "equal weight" rating in a research note on Wednesday, December 14th. Seven research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $52.33.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. RB Capital Management LLC boosted its position in shares of Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company's stock worth $282,000 after buying an additional 341 shares during the period. Ironwood Wealth Management LLC. boosted its position in shares of Pfizer by 1.1% during the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company's stock worth $1,868,000 after buying an additional 400 shares during the period. United Bank boosted its position in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company's stock worth $2,416,000 after buying an additional 290 shares during the period. Ergoteles LLC boosted its position in shares of Pfizer by 136.3% during the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company's stock worth $1,903,000 after buying an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp boosted its position in shares of Pfizer by 6.4% during the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company's stock worth $69,238,000 after buying an additional 79,887 shares during the period. 67.62% of the stock is owned by institutional investors and hedge funds.
Pfizer Company Profile
(Get Rating)
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Featured Stories
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.